Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Go back to Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 42.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.43 | 52 Week High | $26.84 | |||
| Open | $42.43 | 52 Week Low | $9.51 | |||
| Day High | $42.43 | P/E | N/A | |||
| Day Low | $42.43 | EPS | $-2.62 | |||
| Volume | 822 | |||||
